Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer.

Literature DB >> 25759003

Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer.

Aaron I Loochtan¹, Myles S Nickolich², Lisa D Hobson-Webb¹.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2015 PMID： 25759003 DOI： 10.1002/mus.24648

Source DB: PubMed Journal: Muscle Nerve ISSN： 0148-639X Impact factor: 3.217

Keyword Cloud
Cited

× No keyword cloud information.

33 in total

Review 1. Proposed diagnostic and treatment paradigm for high-grade neurological complications of immune checkpoint inhibitors.

Authors: Dustin Anderson; Grayson Beecher; Nabeela Nathoo; Michael Smylie; Jennifer A McCombe; John Walker; Rajive Jassal
Journal: Neurooncol Pract Date: 2018-10-04

2. Ocular myasthenic syndrome, adverse reaction to omalizumab? A case report.

Authors: Willemien S Kalteren; Marco W J Schreurs; Annelies Jorritsma-Smit; Daan J Touw; Jan Willem de Jong; Petra G M A Zweers; Fransje E Reesink
Journal: Br J Clin Pharmacol Date: 2017-06-19 Impact factor: 4.335

Review 3. Update on Chemotherapy-Induced Peripheral Neuropathy.

Authors: Comana Cioroiu; Louis H Weimer
Journal: Curr Neurol Neurosci Rep Date: 2017-06 Impact factor: 5.081

Review 4. B cells in the pathophysiology of myasthenia gravis.

Authors: John S Yi; Jeffrey T Guptill; Panos Stathopoulos; Richard J Nowak; Kevin C O'Connor
Journal: Muscle Nerve Date: 2017-09-30 Impact factor: 3.217

Review 5. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update.

Authors: Hiroki Nagai; Manabu Muto
Journal: Int J Clin Oncol Date: 2018-03-07 Impact factor: 3.402

Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer.

Review 1. Proposed diagnostic and treatment paradigm for high-grade neurological complications of immune checkpoint inhibitors.

2. Ocular myasthenic syndrome, adverse reaction to omalizumab? A case report.

Review 3. Update on Chemotherapy-Induced Peripheral Neuropathy.

Review 4. B cells in the pathophysiology of myasthenia gravis.

Review 5. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update.

Review 6. Neurological Complications of Therapeutic Monoclonal Antibodies: Trends from Oncology to Rheumatology.

Review 7. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

Review 8. Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management.

Review 9. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.

Review 10. Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors.